GlassScriptPhysician profile
Nicholas Karjun Chan
NPI 1396132403
$4,319.43
in general payments reported to CMS, 2019-2025
24 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $1,056 · 2023: $708 · 2024: $1,248 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933 · Entertainment: $39.43 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.07 |
| Entertainment | $39.43 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $986.29 | 2021-2025 | Acthar |
| Alcon Vision LLC | $874.35 | 2022-2025 | Clareon, Hydrus Microstent, Acrysof Iq Panoptix Uv Iol |
| Harrow Eye, LLC | $391.21 | 2024-2025 | Vevye |
| Rxsight INC | $362.94 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sight Sciences, INC. | $299.28 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $214.38 | 2023-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Dompe US, INC. | $129.28 | 2021-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $109.06 | 2024-2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $104.63 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $103.53 | 2023-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $101.56 | 2022-2024 | Lumigan, Vuity |
| Johnson & Johnson Surgical Vision, INC. | $100.05 | 2022-2025 | Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $83.71 | 2022-2023 | Flarex |
| Tarsus Pharmaceuticals, INC. | $78.28 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $66.82 | 2022-2024 | Vabysmo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $60.96 | 2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $46.79 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.17 | 2024-2025 | |
| New World Medical,INC. | $41.64 | 2025 | Clearpath, Streamline, Via360 |
| Optos, INC. | $39.43 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lensar, INC. | $26.63 | 2024 | Lensar Laser System |
| Thea Pharma INC. | $20.69 | 2023 | |
| Aerie Pharmaceuticals, INC. | $19.16 | 2021 | |
| Oyster Point Pharma, INC. | $16.59 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.